| [1] |
Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion[J]. Science,2011,331(6024):1565-1570.
|
| [2] |
Couzin-Frankel J. Breakthrough of the year 2013. Cancer immunotherapy[J]. Science,2013,342(6165):1432-1433.
|
| [3] |
张立煌, 王青青. 恶性肿瘤免疫治疗的现状及展望[J]. 浙江大学学报(医学版),2010,39(4):339-344.
|
| [4] |
Mahoney KM, Rennert PD, Freeman GJ. Combination cancer immunotherapy and new immunomodulatory targets[J]. Nat Rev Drug Discov,2015,14(8):561-584.
|
| [5] |
Ribas A. Tumor immunotherapy directed at PD-1[J]. N Engl J Med,2012,366(26):2517-2519.
|
| [6] |
Hasan A, Ghebeh H,Lehe C,et al. Therapeutic targeting of B7-H1 in breast cancer [J]. Expert Opin Ther Targets, 2011, 15 (10):1211-1225.
|
| [7] |
Nguyen LT, Ohashi PS. Clinical blockade of PD1 and LAG3-potential mechanisms of action[J]. Nat Rev Immunol,2015,15(1):45-56.
|
| [8] |
Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer[J]. N Engl J Med,2012,366(26):2443-2454.
|
| [9] |
Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer[J]. N Engl J Med,2012,366(26):2455-2465.
|
| [10] |
Reiss KA, Forde PM, Brahmer JR. Harnessing the power of the immune system via blockade of PD-1 and PD-L1: a promising new anticancer strategy[J]. Immunotherapy,2014,6(4):459-475.
|
| [11] |
Powles T, Eder JP, Fine GD, et al. MPDL3280A (anti-PD-L1)treatment leads to clinical activity in metastatic bladder cancer[J].Nature,2014,515(7528):558-562.
|
| [12] |
Taube JM, Klein A, Brahmer JR, et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy[J]. Clin Cancer Res, 2014, 20(19):5064-5074.
|
| [13] |
Garon EB,Rizvi NA,Hui R,et al. Pembrolizumab for the treatment of non-small-cell lung cancer[J]. N Engl J Med, 2015, 372(21):2018-2028.
|
| [14] |
Ilie M, Long-Mira E, Bence C, et al. Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies[J]. Ann Oncol,2016,27(1):147-153.
|
| [15] |
Gerlinger M, Rowan AJ, Horswell S, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing[J]. N Engl J Med,2012,366(10):883-892.
|
| [16] |
McLaughlin J, Han G, Schalper KA, et al. Quantitative assessment of the heterogeneity of PD-L1 expression in non-small-cell lung cancer[J]. JAMA Oncol,2016,2(1):46-54.
|
| [17] |
Ilie M, Hofman V, Dietel M,et al. Assessment of the PD-L1 status by immunohistochemistry: challenges and perspectives for therapeutic strategies in lung cancer patients[J]. Virchows Arch,2016.
|
| [18] |
Schalper KA, Velcheti V, Carvajal D, et al. In situ tumor PD-L1 mRNA expression is associated with increased TILs and better outcome in breast carcinomas [J]. Clin Cancer Res, 2014, 20 (10):2773-2782.
|
| [19] |
Mazel M, Jacot W, Pantel K, et al. Frequent expression of PD-L1 on circulating breast cancer cells [J]. Mol Oncol, 2015, 9 (9):1773-1782.
|
| [20] |
Marzec M, Zhang Q, Goradia A, et al. Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274(PD-L1, B7-H1)[J]. Proc Natl Acad Sci U S A, 2008, 105(52):20 852-20 857.
|
| [21] |
Crane CA, Panner A, Murray JC, et al. PI(3) kinase is associated with a mechanism of immunoresistance in breast and prostate cancer[J]. Oncogene,2009,28(2):306-312.
|
| [22] |
Jiang X, Zhou J, Giobbie-Hurder A, et al. The activation of MAPK in melanoma cells resistant to BRAF inhibition promotes PD-L1 expression that is reversible by MEK and PI3K inhibition[J]. Clin Cancer Res,2013,19(3):598-609.
|
| [23] |
Ghebeh H, Lehe C,Barhoush E,et al. Doxorubicin downregulates cell surface B7-H1 expression and upregulates its nuclear expression in breast cancer cells: role of B7-H1 as an anti-apoptotic molecule[J].Breast Cancer Res,2010,12(4): R48.
|
| [24] |
Peng J, Hamanishi J, Matsumura N, et al. Chemotherapy induces programmed cell death-ligand 1 overexpression via the nuclear factorkappaB to foster an immunosuppressive tumor microenvironment in ovarian cancer[J]. Cancer Res,2015,75(23):5034-5045.
|
| [25] |
Twyman-Saint Victor C, Rech AJ, Maity A, et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer[J]. Nature,2015,520(7547):373-377.
|
| [26] |
Beckers RK, Selinger CI, Vilain R, et al. PDL1 expression in triplenegative breast cancer is associated with tumour-infiltrating lymphocytes and improved outcome[J]. Histopathology,2015,48: S146-S147.
|
| [27] |
Mittendorf EA, Philips AV, Meric-Bernstam F, et al. PD-L1 expression in triple-negative breast cancer[J]. Cancer Immunol Res,2014,2(4):361-370.
|
| [28] |
Gatalica Z, Snyder C, Maney T, et al. Programmed cell death 1 (PD-1) and its ligand (PD-L1) in common cancers and their correlation with molecular cancer type[J]. Cancer Epidemiol Biomarkers Prev,2014,23(12):2965-2970.
|
| [29] |
Bertucci F, Finetti P, Colpaert C, et al. PDL1 expression in inflammatory breast cancer is frequent and predicts for the pathological response to chemotherapy [ J]. Oncotarget, 2015, 6 ( 15 ):13 506-13 519.
|
| [30] |
Sabatier R, Finetti P, Mamessier E, et al. Prognostic and predictive value of PDL1 expression in breast cancer[J]. Oncotarget, 2015,6(7):5449-5464.
|
| [31] |
Muenst S, Schaerli AR,Gao F,et al. Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer[J]. Breast Cancer Res Treat,2014,146(1):15-24.
|
| [32] |
Muenst S, Soysal SD,Gao F,et al. The presence of programmed death 1 (PD-1)-positive tumor-infiltrating lymphocytes is associated with poor prognosis in human breast cancer[J]. Breast Cancer Res Treat,2013,139(3):667-676.
|
| [33] |
Sun S, Fei X, Mao Y, et al. PD-1(+) immune cell infiltration inversely correlates with survival of operable breast cancer patients[J].Cancer Immunol Immunother,2014,63(4):395-406.
|
| [34] |
Herbst RS, Soria JC, Kowanetz M, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients[J]. Nature,2014,515(7528):563-567.
|
| [35] |
Tumeh PC, Harview CL, Yearley JH, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance[J]. Nature,2014,515(7528):568-571.
|
| [36] |
Gibson J. Anti-PD-L1 for metastatic triple-negative breast cancer[J].Lancet Oncol,2015,16(6): e264.
|
| [37] |
Ott PA, Hodi FS, Robert C. CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients[J]. Clin Cancer Res,2013,19(19):5300-5309.
|
| [38] |
Kerr KM, Hirsch FR. Programmed death ligand-1 immunohistochemistry:friend or foe? [J]. Arch Pathol Lab Med,2016,140(4):326-331.
|